Ribomic Inc.

Equities

4591

JP3974850004

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-06-11 am EDT			5-day change	1st Jan Change
90 ^JPY	-1.10%		+1.12%	-16.67%

Mar. 07	Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI
Feb. 20	Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	CI

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2021

February 11, 2021

Ribomic Inc. provided non-consolidated earnings guidance for the year ending March 31, 2021. For the year, the company expected operating revenue of JPY 91 million, operating loss of JPY 1,274 million, loss of JPY 1,218 million and loss per share of JPY 47.39.

Latest news about Ribomic Inc.

Ribomic Inc. announced that it has received ¥4.192212 million in funding from SMBC Nikko Securities Inc.	Mar. 06	CI
Ribomic Inc. announced that it expects to receive ¥4.192212 million in funding from SMBC Nikko Securities Inc.	Feb. 19	CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2023	Feb. 13	CI
Ribomic and Ajinomoto Co. Partner for Nucleic Acid Aptamer Research	Jan. 17	MT
Ribomic Enters Into Drug Research Collaboration with Ajinomoto	Jan. 17	MT
RIBOMIC Inc. and Ajinomoto Co., Inc. Announce Joint Research Agreement	Jan. 16	CI
RIBOMIC Phase I and II Data Published in the Eye	Dec. 05	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 13	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2024	23-08-10	CI
Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-10	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
Ribomic Inc. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	23-05-12	CI
Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-12	CI
RIBOMIC, Inc. Announces Start of Administration of RBM-007, Achondroplasia Investigational Drug, to the First Patient in the Early Phase II Study in Japan	23-04-27	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	23-02-10	CI
Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2022	23-02-10	CI
Ribomic Signs JV MoU for Development of RBM-007 Aptamer in China; Shares Rise 3%	22-12-26	MT
RIBOMIC Announces MOU to Establish Joint Venture for Development of RBM-007 in China	22-12-23	CI
Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheimer's Trial Death Count Rises to Two	22-11-29	MT
Ribomic Shares Grow 6% as Tokyo Hospital Registers First Case for Achondroplasia Observational Study	22-11-28	MT
Ribomic Inc. Announces the First Case Registration of Observational Study for RBM-007 Early Phase2 Development Project in Achondroplasia Patients	22-11-28	CI
Ribomic Inc. Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-11	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-11-11	CI
Ribomic Inc. announced that it expects to receive ¥5.1372 million in funding	22-10-10	CI
Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023	22-08-09	CI

Chart Ribomic Inc.

Duration

Period

More charts

Company Profile

RIBOMIC Inc. is engaged in the drug discovery business based on the platform Ribomic Aptamer Refined Therapeutics System related to aptamer drug discovery technology. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
RIBOMIC INC.	-16.67%	21.16M
VERTEX PHARMACEUTICALS INCORPORATED	+18.77%	125B
REGENERON PHARMACEUTICALS, INC.	+14.05%	108B
BIONTECH SE	-7.16%	23.64B
ARGENX SE	+2.62%	22.39B
GENMAB A/S	-12.16%	17.78B
WUXI APPTEC CO., LTD.	-41.74%	16.43B
BEIGENE, LTD.	-13.47%	16.34B
NEUROCRINE BIOSCIENCES, INC.	+2.23%	13.56B
SAREPTA THERAPEUTICS, INC.	+27.13%	11.59B

Bio Therapeutic Drugs

Ribomic Inc.

Equities

4591

JP3974850004

Biotechnology & Medical Research

Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2021

Latest news about Ribomic Inc.

Chart Ribomic Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs